We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

133 hedge funds and large institutions have $365M invested in Rigel Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 50 increasing their positions, 32 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $1.73M | Put options by funds: $881K

56% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 32

0.11% more ownership

Funds ownership: 9.41% → 9.52% (+0.11%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 135 → 133 (-2)

27% less capital invested

Capital invested by funds: $503M → $365M (-$138M)

Holders
133
Holders Change
-2
Holders Change %
-1.48%
% of All Funds
2.96%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
50
Reduced
32
Closed
16
Calls
$1.73M
Puts
$881K
Net Calls
+$848K
Net Calls Change
+$1.49M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$5.69M
2
Citadel Advisors
Citadel Advisors
Florida
+$3.91M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.29M
4
TA
Tamarack Advisers
California
+$2.68M
5
UBS Group
UBS Group
Switzerland
+$1.95M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$7.86M
2
BC
Boxer Capital
California
-$7.45M
3
Millennium Management
Millennium Management
New York
-$2.13M
4
BRF
B. Riley Financial
California
-$1.52M
5
MWNA
Marshall Wace North America
New York
-$1.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$57.5M +$83.2K +2,949 +0.1%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$53.7M +$124K +4,392 +0.2%
BlackRock
3
BlackRock
New York
$31.6M +$252K +8,936 +0.7%
State Street
4
State Street
Massachusetts
$17.5M +$1.12M +39,751 +6%
Citadel Advisors
5
Citadel Advisors
Florida
$15.9M +$3.91M +138,584 +25%
Millennium Management
6
Millennium Management
New York
$15.8M -$2.13M -75,600 -10%
TA
7
Tamarack Advisers
California
$12.7M +$2.68M +95,000 +21%
O
8
OppenheimerFunds
New York
$11.5M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$10.6M -$7.86M -278,641 -38%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$10.5M +$43.7K +1,550 +0.3%
RSCM
11
Rock Springs Capital Management
Maryland
$9.66M +$212K +7,500 +2%
Goldman Sachs
12
Goldman Sachs
New York
$9.48M +$5.69M +201,730 +96%
PAI
13
Palo Alto Investors
California
$9.17M +$56K +1,986 +0.5%
SI
14
Sofinnova Investments
California
$7.78M +$342K +12,124 +4%
NMC
15
NEA Management Company
Maryland
$7.46M – – –
Morgan Stanley
16
Morgan Stanley
New York
$6.49M +$318K +11,263 +4%
CS
17
Candriam SCA
Luxembourg
$5.7M +$593K +21,000 +9%
RPAM
18
Rhenman & Partners Asset Management
Sweden
$5.21M +$426K +15,095 +7%
SCM
19
Sio Capital Management
New York
$5.01M +$951K +33,705 +18%
Hudson Bay Capital Management
20
Hudson Bay Capital Management
Connecticut
$4.83M +$409K +14,500 +7%
Northern Trust
21
Northern Trust
Illinois
$4.63M -$116K -4,121 -2%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$4.44M +$789K +27,942 +17%
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$3.75M +$3.29M +116,669 +252%
Macquarie Group
24
Macquarie Group
Australia
$3.68M – – –
Deutsche Bank
25
Deutsche Bank
Germany
$3.59M -$195K -6,921 -4%
1
2 3 4 5

RIGL Hedge Fund Activity: Q4 2018 in Review

133 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2018, worth a combined $365M — down 27% from $503M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RIGL and 15 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 50 added.

The largest buyer was Goldman Sachs, adding an estimated $5.69M. The largest seller was Vanguard Group, cutting an estimated $7.86M.

  • 133 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2018, down from 135 in Q3 2018.
  • Funds reported $365M of Rigel Pharmaceuticals stock for Q4 2018, down 27% quarter-over-quarter.
  • 15 funds opened new Rigel Pharmaceuticals positions in Q4 2018 and 16 closed out, a net change of -1 holder.
  • The largest Rigel Pharmaceuticals buyer in Q4 2018 was Goldman Sachs, an estimated $5.69M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2018 was Vanguard Group, an estimated $7.86M sold.

Based on aggregated 13F filings for Q4 2018.